Airway abundance of Haemophilus influenzae predicts response to azithromycin in adults with persistent uncontrolled asthma

Steven L. Taylor, Kerry L. Ivey, Peter G. Gibson, Jodie L. Simpson, Geraint B. Rogers

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)

Abstract

Long-term azithromycin treatment reduced exacerbations in adults with persistent symptomatic asthma in the AMAZES trial (Australian and New Zealand Clinical Trials Registry (ANZCTR), number 12609000197235) [1]. However, response to treatment was variable between participants and the characteristics of those who experience most clinical benefit have not been determined. The inability to define a specific population who are more responsive limits the ability to personalise this therapy, which is the goal for airways disease management [2]. With recent studies identifying airway Haemophilus influenzae colonisation as a candidate marker for asthma subgrouping [3, 4], we assessed whether H. influenzae abundance, measured using quantitative PCR (qPCR) [5, 6], predicted the ability of azithromycin therapy to reduce the incidence of acute asthma exacerbations.
Original languageEnglish
Article number2000194
JournalEuropean Respiratory Journal
Volume56
Issue number4
DOIs
Publication statusPublished - 1 Oct 2020

Keywords

  • azithromycin
  • asthma
  • airways disease management

Fingerprint Dive into the research topics of 'Airway abundance of Haemophilus influenzae predicts response to azithromycin in adults with persistent uncontrolled asthma'. Together they form a unique fingerprint.

Cite this